Background: Psoriatic arthritis (APs) is a chronic inflammatory joint disease, that can be treated effectively with synthetic disease modifying anti-rheumatic drugs (DMARDs) and biological agents. Ustekinumab is a monoclonal antibody that inhibits IL-12 and 23 that has recently demonstrated efficacy and safety for the treatment of patients with APs in the PSUMMIT 1 and PSUMMIT 2 studies. Objectives: To evaluate the efficacy of Ustekinumab in our patients with psoriatic arthritis with peripheral involvement in clinical practice conditions. Methods: Descriptive, prospective, longitudinal and open study including patients diagnosed with psoriatic arthritis with peripheral involvement. All patients were given ustekinumab at an initial dose of 45 mg administered subcutaneously followed by another 45 mg dose 4 weeks later and then every 12 weeks. Clinimetric scores (DAS28, MASES, Pain VAS, Clinicians VAS) were assessed and CRP was measured al baseline and after 6 months of treatment. Results: 52 patients were included, 25 were female (48.1%) and 27 male (51.9%). They had a mean age of 46.96±11.39 years, a disease duration of 5.03±5.08 years, and moderate disease activity (DAS 28 of 3.95±0.87), the number of tender and swollen joints were 6.24±4.9 and 2.82±2.36, respectively. The patients had received an average of 1.42±1.75 biological therapies previously. Ustekinumab was prescribed as a first line treatment in 42.3% of patients, 19% after failure of a TNF inhibitor and 38% of patients had received 2 or more biological therapies previously. Ustekinumab was administered alone in 51% of the patients, 36.5% in combination with methotrexate and 11.5% in combination with leflunomide. 23.1% of the patients had dactylitis and 36.5% had enthesitis (mean MASES 1.31±0.86). At 6 months of treatment, there were improvements in the number of tender and swollen joints (mean NAD 4.84±6.4 and NAT 2±3.4 at 6 months, respectively) and MASES index (mean at 6 months, 0.35±0.96). 15 patients had completed at least 6 months of treatment. Improvements in DAS28-CRP scores were observed at 6 months of treatment (3.26±1.62), with a mean DAS28 change after 6 months ( DAS28) Background: According to ACR data 15-20% patients (PTN) with psoriasis are developed with psoriatic arthritis (PsA). Herewith the enthesitis (ETS) as usual is the first signs of PsA manifestations. It is usually asymptomatic at the beginning of the disease, however it is successfully diagnosed with Doppler ultrasound (DU). In average, it takes about 2 years from beginning of the disease till diagnosis PsA is established. PsA treatment is low effective with DMARD, and middle effective with biologic therapy. Wherein no treatment restores the articular changes that have occurred. Thus the actual is to find some resolution to the effective therapy for PTN with psoriasis and also to identify the factors preceding the development of the PsA. Objectives: Consider the application of biologic therapy before the articular changes in PTN with psoriasis and predictors of psoriatic arthritis. Methods: Observed 82 PTN with pustural psoriasis without clinical manifestations of PsA. A physical examination (including PASI), a series of laboratory tests (hematology, CRP, RF, anti -ccp, HLA-B27, uric acid), DU to identify the PsA, its activity, as well as to the exclusion of other types of arthritis were used. Results: 3,7% PTN were diagnosed with PsA with articular changes. 23,1% PTN were founded with enthesitis. The remaining 73,2% PTN had no signs of enthesitis during physical examination and DU. PTN with enthesitis were divided into 2 groups. I -47% PTN (22% of them had clinical manifestations of enthesitis; the average group PASI-42,4±8,2) received a 52-weeks course of ustekinumab (45 mg administered subcutaneously initially and 4 weeks later, followed by 45 mg administered subcutaneously every 12 weeks). II group -53% people (20% PTN had clinical manifestations of enthesitis; the average group PASI-43,6±9,0) did not receive biological therapy, but only standart treatment for psoriasis. After 1 year follow-up after completion of the treatment course -11% PTN from group I developed PsA with articular changes. From the group II in 80% PTN developed PsA with articular changes. The average group I PASI-7,6±1,5; the average group PASI-6,2±1,3. (p <0,05) Conclusions: Thus, the ustekinumab use in psoriatic PTN with enthesitis possibly may be reasonable and will hinder the development of PsA. Ustekinumab is also high effective for the improving of the psoriasis skin symptoms. DU is the high effective diagnostic method for detecting enthesitis without clinical manifestations. Frequency of screening DU in PTN with psoriasis, for the early detection of enthesitis is the perspective for further study. Background: Psoriatic arthritis (PsA) is an immune-mediated disease affecting skin, joints, entheses, spine, and the vasculature [1, 2] . Increased inflammatory mediators are held responsible for impacts on the skin and musculoskeletal system as well as comorbid situations including cardiovascular disease (CVD) and metabolic syndrome [3] . PTX 3 is an acute phase reactant that has prognostic value for rheumatoid arthritis (RA), vasculitis, and psoriasis that also stands out as a novel biomarker for CVD in new researches [4] .
Objectives: This study aims to assess the association between PTX 3 levels, disease activity and CVD risk in patients with PsA. Methods: A total of 38 PsA patients applying to Ankara University Faculty of Medicine, Rheumatology Polyclinic and 32 age and sex-matched controls were enrolled in the study. tender and swollen joint counts, patient's and doctor's global assesment on VAS, ESR, CRP, fasting insulin, fasting glucose, total cholesterol, HDL, and LDL were noted. Also body mass index (BMI) and HOMA-IR score were calculated. Carotid intima media thickness (cIMT) was bilaterally assessed by Doppler ultrasound. Results: The mean age was 49.5 in patients and 48.9 in controls. Sixty percent of the patients and 50% of controls were female. Of the patients, 15 (39%) used DMARD monotherapy, 8 (21%) used DMARD combination therapies, and 15 (39%) used anti TNF therapies. There was no statistically significant difference between groups in terms of hypertension, LDL levels, and smoking status (p:0.775, p:0.228, p:0.136 respectively). PsA patients had significantly higher BMI scores (p:0.03). Insulin levels and HOMA-IR scores were significantly higher among PsA patients compared to controls (p:0.001, p:0.005). There was statistically significant difference between groups in terms of PTX 3 (p<0.001). PTX 3 was significantly correlated with HOMA-IR and cIMT (r:0.243 p:0.043 and r:0.421 p:0.001 respectively). However no correlation between PTX 3 and disease activity parameters such as ESR, CRP, SJC, TJC, and VAS-pain was detected (p:0.824, 0.662, 0.922, 0.924, 0.410 respectively). There was not significant difference in terms of PTX-3 levels between PsA patients on biologic treatment or other treatment strategies (p:0.27). Conclusions: Elevated levels of PTX 3 may be associated with cardiovascular involvement in PsA patients independent from the disease activity. This marker might be used for risk prediction for CVD or may represent a target for new therapies. 
